169264 ⎘
Investigating or analysing materials by specific methods not covered by groups -; Biological material, e.g. blood, urine ; Haemocytometers; Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing; Immunoassay; Biospecific binding assay; Materials therefor for cancer; Specifically defined cancers of skin, e.g. melanoma
MOLECULAR PROFILING OF TUMORS
#2ANTIBODIES SPECIFIC TO MUC18
#3TREATMENT OF SQUAMOUS CELL CARCINOMA
#4METHODS FOR MONITORING MOLECULAR BIOMARKERS FOR AGING AND DISEASE
#5BIOMARKERS FOR CANCER THERAPEUTICS
#6MOLECULAR PROFILING OF TUMORS
#7BIOMARKERS FOR DISEASE PROGRESSION AND/OR RECURRENCE IN SQUAMOUS CELL CARCINOMA
#8Method of Predicting a Patient's Benefit From Therapy with an Immune Checkpoint Inhibitor
#9CHLOROTOXIN CONJUGATES AND METHODS OF USE THEREOF
#10METHODS FOR DESIGNING IMMUNOTHERAPIES AND TREATMENTS USING SAME
#11RECEPTOR FOR VISTA
#12NOVEL BIOMARKER FOR DETECTION OF CANCER METASTASIS
#13ASSESSING AND TREATING MELANOMA
#14PHARMACEUTICAL COMBINATION AND TUMOR TREATMENT
#15PROGNOSIS AND PREDICTIVE BIOMARKERS AND BIOLOGICAL APPLICATIONS THEREOF
#16METHOD OF PREDICTING RESPONSE TO IMMUNOTHERAPY
#17TREATMENT AND DIAGNOSIS OF MELANOMA
#18FUCOSYLATION AND IMMUNE SURVEILLANCE IN MELANOMA
#19COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY
#20Indole Carboxylic Acid Compound, Indole Carboxylic Acid Compound Mixture, and Analytical Method
#21METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR
#22MARKERS, METHODS AND SYSTEMS FOR IDENTIFYING CELL POPULATIONS, DIAGNOSING, MONITORING, PREDICTING AND TREATING CONDITIONS
#23MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors
#24ANTIGEN-COUPLED IMMUNOREAGENTS
#25PERIPHERAL BLOOD PHENOTYPE LINKED TO OUTCOMES AFTER IMMUNOTHERAPY TREATMENT
#26GDF-15 AS A DIAGNOSTIC MARKER FOR MELANOMA
#27PLASMA EXCHANGE REMOVAL OF SPD-L1
#28ENHANCING ANTI-TUMOR RESPONSE IN MELANOMA CELLS WITH DEFECTIVE STING SIGNALING
#29RECEPTOR FOR VISTA
#30RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R
#31COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY
#32STROMAL GENE SIGNATURES FOR DIAGNOSIS AND USE IN IMMUNOTHERAPY
#33METHOD FOR PROGNOSIS PREDICTION OF SKIN CANCER AND USE THEREOF
#34MOLECULAR PROFILING OF TUMORS
#35DIAGNOSTIC AND PROGNOSTIC UTILITY OF EXOSOMES IN IMMUNOTHERAPY
#36CHEMICAL COMPOSITIONS AND METHODS OF USE
#37Anti-renalase antibodies for the treatment and prevention of diseases and disorders
#38Tissue-Derived Extracellular Vesicles and Their Use as Diagnostics
#39MELANOMA BIOMARKERS
#40METHOD OF IMPROVING EFFICACY OF MELANOMA TREATMENT
#41TREATMENT OF PD-L1-POSITIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY
#42SOLUBLE PROGRAMMED CELL DEATH PROTEIN-1 AS A BIOMARKER IN CANCER PATIENTS
#43METHODS AND COMPOSITIONS FOR TREATMENT OF ENDOTHELIN B RECEPTOR EXPRESSING TUMORS
#44GDF-15 AS A DIAGNOSTIC MARKER TO PREDICT THE CLINICAL OUTCOME OF A TREATMENT WITH IMMUNE CHECKPOINT BLOCKERS
#45TUMOR CELL-DERIVED EXOSOMES AND THEIR APPLICATIONS
#46BIOMARKERS OF THERAPEUTIC RESPONSIVENESS
#47METHODS OF DETERMINING PATIENT POPULATIONS AMENABLE TO IMMUNOMODULATORY TREATMENT OF CANCER
#48ANTI-VISTA ANTIBODIES AND FRAGMENTS
#49LIPID BIOMARKERS FOR CANCER SCREENING AND MONITORING
#50METHODS OF IDENTIFYING RESPONSES TO MAP KINASE INHIBITION THERAPY
#51TREATMENT OF PD-L1-NEGATIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY
#52SYSTEMS AND METHODS FOR THE MOLECULAR QUANTIFICATION OF SKIN DAMAGE IN SKIN
#53IMMUNE CELL TRAPPING DEVICES AND METHODS FOR MAKING AND USING THE SAME
#54Galectin-7-specific monovalent antibodies and uses thereof
#55ANTIBODIES SPECIFIC TO MUC18
#56CLASS I MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS
#57USE OF CIRCULATING TUMOR CELL MITOTIC INDEX IN CANCER STRATIFICATION AND DIAGNOSTICS
#58METHOD FOR IDENTIFICATION OF CANCER PATIENTS WITH DURABLE BENEFIT FROM IMMUNOTEHRAPY IN OVERALL POOR PROGNOSIS SUBGROUPS
#59COMPOSITIONS AND METHODS FOR PREVENTION AND REDUCTION OF METASTASIS
#60METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
#61MONOCLONAL ANTIBODIES AGAINST LORICRIN
#62COMPOSITIONS AND METHODS FOR FLUID BIOPSY OF MELANOMA
#63IMAGING MASS SPECTROMETRY AND USES THEREOF
#64Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
#65BIOMARKERS FOR CANCER THERAPY
#66Combination Therapy for Melanoma
#67Monoclonal antibodies against Ambra-1
#68METHODS, KITS, AND SYSTEMS FOR SCORING THE IMMUNE RESPONSE TO CANCER
#69TREATMENT OF SQUAMOUS CELL CARCINOMA
#70METHODS OF IDENTIFYING RESPONSES TO MAP KINASE INHIBITION THERAPY
#71DATA PROCESSING SYSTEM FOR IDENTIFYING A THERAPEUTIC AGENT
#72Eosinophil Cationic Protein (ECP) as a Tumor Marker for Malignant Tumors
#73MELANOMA CHECKPOINT INHIBITOR DETECTION AND TREATMENT
#74Treatment and diagnosis of melanoma
#75ENHANCING ANTI-TUMOR RESPONSE IN MELANOMA CELLS WITH DEFECTIVE STING SIGNALING
#76ANTIBODIES ANTI TUMOR ASSOCIATED ANTIGENS AND METHOD FOR OBTAINING THEM
#77ANTIGEN-COUPLED IMMUNOREAGENTS
#78METHOD TO PERFORM DIAGNOSIS AND PROGNOSIS OF MELANOMA AND KIT
#79Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods
#80THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS
#81Nanoengineered surfaces for cancer biomarker capture
#82METHODS AND COMPOSITIONS FOR TREATING MELANOMA RESISTANT
#83Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof
#84METHOD AND SYSTEM FOR PREDICTING RECURRENCE AND NON-RECURRENCE OF MELANOMA USING SENTINEL LYMPH NODE BIOMARKERS
#85MEK1 mutation conferring resistance to RAF and MEK inhibitors
#86Biomarkers for cancer therapeutics
#87Markers, methods and systems for identifying cell populations, diagnosing, monitoring, predicting and treating conditions
#88GDF-15 AS A DIAGNOSTIC MARKER FOR MELANOMA
#89Fucosylation and immune surveillance in melanoma
#90MOLECULAR PROFILING FOR CANCER
#91Methods and compositions for treatment of endothelin B receptor expressing tumors
#92IMMUNOGENIC COMPOSITIONS AND USES THEREFOR
#93Extracellular vesicle proteins and their use for cancer diagnosis, predicting response to therapy, and treatment
#94TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY
#95Method to diagnose malignant melanoma in the domestic dog
#96Treatment and diagnosis of melanoma
#97DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES
#98Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy
#99IN VITRO METHOD FOR DETECTING TUMOR GROWTH AND DIAGNOSING OR PROGNOSTICATING THE RISK OF METASTASIS IN A HUMAN SUBJECT THAT HAS BEEN DIAGNOSED WITH UVEAL MELANOMA
#100METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR
#101METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES
#102METHOD FOR DETERMINING THE POTENTIAL EFFICACY OF ANTICANCER TREATMENT
#103Biomarkers of disease
#104Radiotherapeutic and companion imaging agents to target MC1R
#105Dynamic BH3 profiling
#106Tissue-derived extracellular vesicles and their use as diagnostics
#107A METHOD FOR CHARACTERIZING MELANOCYTIC LESIONS
#108METHOD OF PREDICTING RESPONSE TO IMMUNOTHERAPY
#109Method of treating melanoma using an inhibitor of an atypical protein kinase C
#110BIOMARKERS FOR DISEASE PROGRESSION IN MELANOMA
#111Anti-vista antibodies and fragments
#112MOLECULAR PROFILING OF TUMORS
#113NEO-ANTIGEN SPECIFIC T CELLS
#114Method for Treating Cancer
#115DDX43 AS A BIOMARKER OF RESISTANCE TO MEK1/2 INHIBITORS
#116Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
#117Pathogenic biomarkers and serum extracellular vesicular biomarkers associated with vascular malformation of endothelial cells, and uses thereof
#118Method for the diagnosis and prognosis of cancer
#119METHOD OF IMPROVING EFFICACY OF MELANOMA TREATMENT
#120Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
#121Methods for predicting responsiveness of a cancer to an immunotherapeutic agent and methods of treating cancer
#122METHODS AND KITS FOR PREDICTING THE SENSITIVITY OF A SUBJECT TO IMMUNOTHERAPY
#123Methods of diagnosing cancer using cancer testis antigens
#124Methods and Systems for Predicting Response to Immunotherapies for Treatment of Cancer
#125Compositions for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
#126TREATMENT OF PD-L1-NEGATIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY
#127Methods of detecting DDR2 mutations
#128Methods and materials for staging and treating skin cancer
#129C-RAF Mutants that Confer Resistance to RAF Inhibitors
#130METHOD FOR PREDICTING THE RESPONSE OF MELANOMA PATIENTS TO A MEDICAMENT
#131STROMAL GENE SIGNATURES FOR DIAGNOSIS AND USE IN IMMUNOTHERAPY
#132COMPOSITIONS AND METHODS FOR IDENTIFYING A RISK OF CANCER IN A SUBJECT
#133Lysosomal acid lipase and PPAR gamma ligands as immune therapies for cancer treatment
#134METHODS AND SYSTEMS FOR DETECTING MELANOMA
#135Immune gene signatures in treating breast cancer
#136GDF-15 AS A DIAGNOSTIC MARKER FOR MELANOMA
#137Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
#138Death receptors as markers for rhTRAIL-sensitivity
#139METHODS FOR MELANOMA DETECTION
#140GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
#141Method for predicting the response of melanoma patients to targeted pharmacotherapy
#142Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods
#143FALZ for use as a target for therapies to treat cancer
#144H3T3A mutant protein efficiently reduces H3T3P and causes increased cell death of rapidly dividing cells
#145Three-dimensional fibroblast aggregate and in vitro 3D skin dermis model comprising same
#146CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
#147COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY
#148MEK1 mutation conferring resistance to RAF and MEK inhibitors
#149INHIBITION OF CANCER GROWTH AND METASTASIS
#150THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS
#151Ambra-1 and Loricrin as biomarkers for disease progression in melanoma
#152Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
#153METHOD FOR STRATIFICATION OF MELANOMA PATIENTS BY DETERMINATION OF OXYGEN CONSUMPTION, PPARGC1A, PPARGC1B AND MITF LEVELS
#154Immune cell trapping devices and methods for making and using the same
#155Use of circulating tumor cell mitotic index in cancer stratification and diagnostics
#156Treatment and diagnosis of melanoma
#157Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy
#158RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R
#159Method of predicting effect of treatment by PD-1/PD-L1 blockade using abnormality of PD-L1 (CD274) as index
#160Immunohistochemical assay for detecting expression of programmed death ligand 1 (PD-L1) in tumor tissue
#161METHOD FOR DETECTION OF L523S EXPRESSION IN BIOLOGICAL SAMPLES
#162Methods of determining patient populations amenable to immunomodulatory treatment of cancer
#163Anti-CSPG4 reagents and methods of treating cancer
#164Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy
#165METHOD FOR TREATING CANCER
#166MOLECULAR PROFILING FOR CANCER
#167TARGETING GDF6 AND BMP SIGNALING FOR ANTI-MELANOMA THERAPY
#168METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
#169METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
#170BIOMARKERS AND TARGETS FOR CANCER IMMUNOTHERAPY
#171PRKACB FUSIONS
#172Method of diagnosing and monitoring bladder cancer
#173Biomarker And Therapy Intervention For Malignancy Risk Patients
#174Method of treating melanoma using an inhibitor of an atypical protein kinase C
#175Histochemical assay for evaluating expression of programmed death ligand 1 (PD-L1)
#176Apilimod for use in the treatment of melanoma
#177PRO-ANGIOGENIC AND ANTI-ANGIOGENIC HEMATOPOIETIC PROGENITOR CELL POPULATIONS
#178Anti-MFI2 antibodies and methods of use
#179Treatment and diagnosis of melanoma
#180Method for evaluating efficacy of chemoradiotherapy against squamous cell carcinoma
#181Methods for Predicting and Monitoring Cancer Patients' Response to Teatment by Measuring Myeloid Derived Suppressor Cells (MDSCs)
#182Methods of detecting DDR2 mutations
#183ANGIOPOITEN-2 BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT RESPONSE
#184Presence of Phosphorylated Tau Protein in the Skin of Neurodegenerative Disease and SCIS, SCC, and BCC
#185Method to diagnose malignant melanoma in the domestic dog
#186Biomarkers of therapeutic responsiveness
#187COMPOSITIONS AND METHODS FOR FLUID BIOPSY OF MELANOMA
#188Method of diagnosing and monitoring bladder cancer and melanoma
#189Method for treating melanoma
#190DR6 Receptor Mediates the Leukemia Differentiation Activity of Angiocidin: A Potent Anti-Tumor Peptide
#191METHODS OF TREATING MELANOMA
#192Methods and systems for predicting response to immunotherapies for treatment of cancer
#193Antibody fragments for detecting cancer and methods of use
#194Anti-DLL3 antibodies and drug conjugates for use in melanoma
#195Method and biomarker for detecting metastasis of sarcoma
#196Anti-vista antibodies and fragments
#197Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods
#198Method of treating cancer using immune checkpoint inhibitor
#199Compositions and methods for treating cancers associated with ETBR activation
#200METHODS AND COMPOSITIONS FOR IMMUNOMODULATION
#201Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
#202Methods, kits, and systems for scoring the immune response to cancer
#203Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
#204miR-211 expression and related pathways in human melanoma
#205Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody
#206COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF MELANOMA USING PD-L1 ISOFORMS
#207Treatment and diagnosis of melanoma
#208Immune gene signatures in cancer
#209Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
#210METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS
#211Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma
#212Kynurenine Pathway Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
#213Inhibition of a lncRNA for treatment of melanoma
#214Antigen-coupled immunoreagents
#215DDX43 as a biomarker of resistance to MEK1/2 inhibitors
#216SPARC AND METHODS OF USE THEREOF
#217Markers for the epithelial and proliferative or mesenchymal invasive phenotype of human neoplasia
#218MOLECULAR PROFILING OF TUMORS
#219SYSTEMS AND METHODS FOR THE MOLECULAR QUANTIFICATION OF SKIN DAMAGE IN SKIN
#220Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells
#221Immunogenic tumor associated stromal cell antigen peptides and methods of their use
#222MEK1 mutation conferring resistance to RAF and MEK inhibitors
#223COMPOSITIONS AND METHODS FOR IDENTIFYING A RISK OF CANCER IN A SUBJECT
#224Method for the diagnosis and prognosis of cancer
#225DETECTING CANCER WITH ANTI-CXCL16 AND ANTI-CXCR6 ANTIBODIES
#226Methods for detecting and treating variants of seborrheic keratoses
#227COMPOSITIONS AND METHODS FOR INHIBITING CHEMORESISTANCE IN CANCER AND IMPROVING RESPONSE TO THERAPY
#228Compositions and methods for detecting cancer metastasis
#229Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
#230FALZ for use as a target for therapies to treat cancer
#231Methods of identifying responses to map kinase inhibition therapy
#232Replication protein
#233Therapeutic and diagnostic methods relating to cancer stem cells
#234Combinatorial compositions and methods for treatment of melanoma
#235USING GALECTIN-BINDING CARBOHYDRATES AS PREDICTORS OF MELANOMA PROGRESSION AND METASTASIS
#236METHOD FOR OBTAINING DATA THAT ARE USEFUL FOR THE DIAGNOSIS, PROGNOSIS AND CLASSIFICATION OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND/OR LUNG CANCER
#237Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles
#238Inhibitors of atypical protein kinase C and their use in treating hedgehog pathway-dependent cancers
#239Inhibition of cancer growth and metastasis
#240B7-H3 AS A BIOMARKER FOR DIAGNOSING THE PROGRESSION AND EARLY LYMPH NODE METASTASIS OF CANCER
#241Method of treatment of SETDB1 expressing cancer
#242METHODS FOR HEAD AND NECK CANCER PROGNOSIS
#243Methods for predicting the sensitivity of a subject to immunotherapy
#244Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma
#245MIR-18B for use as a marker of cancer progression and target for therapies to treat cancer
#246Kit for diagnosing malignant melanoma
#247USE OF CASPASE 3 ACTIVITY AND ITS INHIBITORS
#248METHODS AND SYSTEM FOR DETECTING MELANOMA
#249Methods and Compositions for Treating or Diagnosing Melanoma
#250Methods of detecting and treating stem-cell containing solid tumors
#251C-RAF mutants that confer resistance to RAF inhibitors
#252Melanoma antigen peptide and uses thereof
#253Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy
#254Anti-CXCR1 compositions and methods
#255DETECTION OF TUMOR MICROENVIRONMENT WITH CHLOROTOXIN CONJUGATES
#256Treatment of drug resistant cancer
#257Method for detection of L523S expression in biological samples
#258Monoclonal antibodies and diagnostic uses thereof
#259Treatment and diagnosis of melanoma
#260Collateral gene inactivation biomarkers and targets for cancer therapy
#261LKB1/STK11 DELETION IN MELANOMA AND RELATED METHODS
#262METHODS FOR DETECTING HUMAN PAPILLOMAVIRUS AND PROVIDING PROGNOSIS FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA
#263Immunogenic tumor associated stromal cell antigen peptides and methods of their use
#264BIOMARKERS OF THERAPEUTIC RESPONSIVENESS
#265DDR2 mutations as targetable features of melanoma or basal cell carcinoma
#266Insulin-like growth factor binding protein 7 for treatment of cancer
#267Coiled coil helix cristae morphology 1 (CHCM1) tumor marker and cancer therapeutic target
#268Compounds for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
#269PROGNOSTIC AND THERAPEUTIC SIGNATURE FOR MALIGNANT MELANOMA
#270Melanoma antigen peptide and uses thereof
#271Method for differentiating spitz nevi from spitzoid malignant melanoma
#272Methods, agents and peptides for inducing an immune response to matrix metalloproteinase-2 expressing tumors
#273Combinations of therapeutic agents for treating melanoma
#274Upregulation of rack-1 in melanoma and its use as a marker
#275Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E
#276Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
#277COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF B-RAF INHIBITOR-RESISTANT MELANOMAS
#278Cancer treatment
#279MAGE antigen binding proteins
#280Method for diagnosing melanocytic proliferations
#281METHODS OF DETECTING AND TREATING CANCERS USING AUTOANTIBODIES
#282Stromal Antigen 2 (STAG2) Compositions and Methods
#283Monoclonal antibodies and diagnostic uses thereof
#284Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
#285Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
#286USE OF CCR9, CCL25/TECK, AND INTEGRIN alpha4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE
#287METHODS FOR DIAGNOSIS AND TREATMENT OF CUTANEOUS T CELL LYMPHOMAS
#288Photosensitizer composition for treating skin disorders
#289Inhibitors of atypical protein kinase C and their use in treating hedgehog pathway-dependent cancers
#290METHODS FOR DIAGNOSIS AND TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS
#291Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
#292MELANOMA PROGNOSTIC MODEL USING TISSUE MICROARRAYS AND GENETIC ALGORITHMS
#293RBM3 as a marker for malignant melanoma prognosis
#294Polynucleotide Fragments of an Infectious Human Endogenous Retrovirus
#295Isolation and use of melanoma cancer stem cells
#296DETERMINING SENSITIVITY OF CELLS TO B-RAF INHIBITOR TREATMENT BY DETECTING KRAS MUTATION AND RTK EXPRESSION LEVELS
#297Cancer treatment
#298Use of eIF3m for the diagnosis and treatment of cancer
#299SERUM BIOMARKERS FOR MELANOMA METASTASIS
#300METHODS OF ASSESSING ACTIVITY OF A POLYSACCHARIDE COMPOSITION